279Val→Phe Polymorphism of lipoprotein-associated phospholipase A2 resulted in changes of folding kinetics and recognition to substrate

INTRODUCTION PLA2G7 encodes Lp-PLA2 having role in the formation of atherosclerotic plaques by catalyzing its substrate, phosphatydilcholine (PC), to be pro-inflammatory substances. The increased risk for coronary artery disease (CAD) in Asian population has been related with this enzyme. 279(Val→Phe) variant was reported to have a protective role against CAD due to, in part, secretion defect or loss of enzymatic function. Therefore, We study folding kinetics and enzyme-substrate interaction in 279(Val→Phe) by using clinical and computational biology approach. METHODS Polymorphisms were detected by genotyping among 103 acute myocardial infarction patients and 37 controls. Folding Lp-PLA2 was simulated using GROMACS software by assessing helicity, hydrogen bond formation and stability. The interactions of Lp-PLA2 and its substrate were simulated using Pyrx software followed by molecular dynamics simulation using YASARA software. RESULT Polymorphism of 279(Val→Phe) was represented by the change of nucleotide from G to T of 994th PLA2G7 gene. The folding simulation suggested a decreased percentage of α-helix, hydrogen bond formation, hydrogen bond stability and hydrophobicity in 279(Val→Phe). The PC did not interact with active site of 279(Val→Phe) as paradoxically observed in 279 valine. 279(Val→Phe) polymorphism is likely to cause unstable binding to the substrate and decrease the enzymatic activity as observed in molecular dynamics simulations. The results of our computational biology study supported a protected effect of 279(Val→Phe) Polymorphism showed by the odd ratio for MI of 0.22 (CI 95% 0.035-1.37) in this study. CONCLUSION 279(Val→Phe) Polymorphism of Lp-PLA2 may lead to decrease the enzymatic activity via changes of folding kinetics and recognition to its substrate.

[1]  M. Emi,et al.  Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients , 2004, Journal of Human Genetics.

[2]  H. Hakonarson,et al.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis. , 2012, Journal of the American College of Cardiology.

[3]  N. Kallenbach,et al.  The role of context on α‐helix stabilization: Host‐guest analysis in a mixed background peptide model , 1997, Protein science : a publication of the Protein Society.

[4]  Satoshi Takahashi,et al.  Collapse and search dynamics of apomyoglobin folding revealed by submillisecond observations of alpha-helical content and compactness. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Terry K. Smith,et al.  The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholine , 2010, IUBMB life.

[6]  D. Wolf,et al.  Degradation of misfolded protein in the cytoplasm is mediated by the ubiquitin ligase Ubr1 , 2008, FEBS letters.

[7]  S. Servi,et al.  Synthesis of Lysophospholipids , 2010, Molecules.

[8]  M. Minch An Introduction to Hydrogen Bonding (Jeffrey, George A.) , 1999 .

[9]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[10]  D. Levandier,et al.  H2+(X,v+=0~15,N+=1)+Heプロトン移動反応のパルス電界イオン化光電子二次イオンコインシデンス研究 , 2005 .

[11]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[12]  I. Bahar,et al.  Role of water on unfolding kinetics of helical peptides studied by molecular dynamics simulations. , 1997, Biophysical journal.

[13]  P. Biswas,et al.  Hydrogen bond dynamics in intrinsically disordered proteins. , 2014, The journal of physical chemistry. B.

[14]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules J. Am. Chem. Soc. 1995, 117, 5179−5197 , 1996 .

[15]  E. Dennis,et al.  Phospholipase A2 Biochemistry , 2009, Cardiovascular Drugs and Therapy.

[16]  S. D. de Leeuw,et al.  Fast in silico protein folding by introduction of alternating hydrogen bond potentials. , 2008, Biophysical journal.

[17]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[18]  J. Adamski,et al.  Evidence Supporting a Key Role of Lp-PLA2-Generated Lysophosphatidylcholine in Human Atherosclerotic Plaque Inflammation , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Subbaiah,et al.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology. , 2010, Antioxidants & redox signaling.

[20]  Tracy E. Macaulay,et al.  Platelet Activating Factor , 2015 .

[21]  G. Vriend,et al.  Fast empirical pKa prediction by Ewald summation. , 2006, Journal of molecular graphics & modelling.

[22]  Xiao-bo Hu,et al.  Association of Lipoprotein-Associated Phospholipase A2 with Characteristics of Vulnerable Coronary Atherosclerotic Plaques , 2011, Yonsei medical journal.

[23]  Dylan L. Steen,et al.  Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events , 2013, Cardiology and Therapy.

[24]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[25]  Bin Zhou,et al.  [Correlation between desmin gene, platelet-activating factor acetylhydrolase gene and dilated cardiomyopathy]. , 2006, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.

[26]  G. Zimmerman,et al.  Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. , 1996, The Journal of clinical investigation.

[27]  K. Sanbonmatsu,et al.  α-Helical stabilization by side chain shielding of backbone hydrogen bonds , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[29]  R. Sauer,et al.  Tolerance of a protein helix to multiple alanine and valine substitutions. , 1998, Folding & design.

[30]  G. Rose,et al.  Is protein folding hierarchic? II. Folding intermediates and transition states. , 1999, Trends in biochemical sciences.

[31]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[32]  Y. Duan,et al.  The fast-folding HP35 double mutant has a substantially reduced primary folding free energy barrier. , 2008, The Journal of chemical physics.

[33]  S. Scheiner,et al.  Comparison of various types of hydrogen bonds involving aromatic amino acids. , 2002, Journal of the American Chemical Society.

[34]  N. Karnik,et al.  Antioxidant status in patients with acute myocardial infarction , 2007, Indian Journal of Clinical Biochemistry.

[35]  P. Argos,et al.  Knowledge‐based protein secondary structure assignment , 1995, Proteins.

[36]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[37]  P. Debenedetti,et al.  A computational study of hydration, solution structure, and dynamics in dilute carbohydrate solutions. , 2005, The Journal of chemical physics.

[38]  Jie Liang,et al.  CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues , 2006, Nucleic Acids Res..

[39]  François Stricher,et al.  A graphical interface for the FoldX forcefield , 2011, Bioinform..

[40]  Chartchalerm Isarankura-Na-Ayudhya,et al.  Molecular Docking of Aromatase Inhibitors , 2011, Molecules.

[41]  E. Lindahl,et al.  Implementation of the CHARMM Force Field in GROMACS: Analysis of Protein Stability Effects from Correction Maps, Virtual Interaction Sites, and Water Models. , 2010, Journal of chemical theory and computation.

[42]  Dima Kozakov,et al.  Rigid Body Energy Minimization on Manifolds for Molecular Docking. , 2012, Journal of chemical theory and computation.

[43]  U. Samanta,et al.  Crystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase , 2008, Journal of Biological Chemistry.

[44]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[45]  M. H. Raitt Are n-3 Polyunsaturated Fatty Acids Antiarrhythmic in the Absence of Ischemia? , 2009, Cardiovascular Drugs and Therapy.

[46]  G. A. Jeffrey,et al.  An Introduction to Hydrogen Bonding , 1997 .

[47]  Martin F. Jarrold,et al.  Conformations of Unsolvated Valine-Based Peptides , 2000 .

[48]  Keizō Inoue,et al.  Plasma platelet activating factor-acetylhydrolase (PAF-AH). , 2003, Progress in lipid research.

[49]  G. Shi,et al.  Platelet‐activating factor‐acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction , 2006, Journal of thrombosis and haemostasis : JTH.

[50]  J. H. Lee,et al.  The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. , 2006, The Journal of clinical endocrinology and metabolism.

[51]  L. Cardon,et al.  Carriage of the V279F Null Allele within the Gene Encoding Lp-PLA2 Is Protective from Coronary Artery Disease in South Korean Males , 2011, PloS one.

[52]  U. Samanta,et al.  Crystal Structure of Human Plasma Platelet-activating Factor Acetylhydrolase , 2008, Journal of Biological Chemistry.